Published :
Tables : 68
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3268
Clinical Trials Market is poised to value USD 69742.5 million by 2028 end at a CAGR of 5.8% during the forecast period 2022 to 2028. Increased occurrence of appalling diseases, acceptance of novel clinical trial technologies, increased demand for clinical trials from emerging nations are some of the key factors responsible for the proliferation of the market. Furthermore, the soaring insistence for contract research organizations for conducting clinical trials is predicted to boost the clinical trials market growth. CROs are more diversified than pharma companies in performing clinical trials over a wide range of regions and drug development in specific therapeutic areas shall further propel the market growth. As per the BioOutsource report, 2017, the biosimilar testing is projected to witness a significant growth in the United States and this can be credited to factors like FDA addressing the dearth of clear guidance regarding the usage of biosimilars, particularly the method in which the developers offer drugs similar to the original product. Hospira, in January 2015, developed Epoetin Alfa, a version of Epogen, which received an approval from the FDA within a year. Furthermore, the regional distribution of clinical trials is gradually shifting from developed to developing nations and the increased expenditure of these trials has made the ley players to shift emphasis on regions like Eastern and Central Europe, Latin America and Middle East & Africa for faster recruitment of patients and cost efficiency. Such factors are touted to boost the proliferation of the market. The digitization in researches related to the field of biomedicals has opened lucrative opportunities for the market growth. Acceptance of advanced systems like electronic data capture has helped companies in managing patient data, thereby reducing the cost of monitoring the cost and for improves patient compliance. Furthermore, managing patient data with digitization shall help in reducing the errors related to clinical trials and can satisfy strict regulations. Such factors have contributed to the proliferation of the market. Market Segmentation: By Phase Phase I Phase II Phase III Phase IV By Study Design Interventional Observational Expanded Access By Indication Inflammation Pain Management Central Nervous System Conditions Oncology Obesity Cardiovascular Diabetes Others By Region North America Europe Asia-Pacific Latin America Middle East and Africa The market is classified into phase, study design, indication and region. The phase segment is categorised into phase I, phase II, phase III and phase IV. The phase III segment held the largest clinical trials market share owing to the huge sample population and the steep cost of these trials. The phase I clinical trials have a sample population of over 100 people, and it helps in evaluating the molecule tolerability which is considered ad the end point of trial approval. Other studies like drug and food interactions are needed to be performed. As per the Food and Drug Association, over 65% of medications move from phase I to phase II. The study design segment is fragmented into observational, interventional and expanded access. The interventional segment is anticipated to lead the market during the forecasted timeframe. The primary motive of interventional trial is to identify about a specific intervention and this method is frequently used for clinical trials. According to the stats provided by the FDA, USA, 2017, over 120,000 trials were performed using this method. Owing to the rising insistence for this study type in clinical trials, this segment is predicted to proliferate at a significant rate during the forecasted time frame. The indication segment is bifurcated into inflammation, pain management, central nervous system conditions, oncology, obesity, cardiovascular, diabetes and others. The oncology segment is anticipated to proliferate at a significant rate during the forecasted timeframe. Regional Analysis: The North America region is expected to lead the market owing to rising research and development activities and increased acceptance of these clinical research technologies in the region. North America region has the greatest number of clinical trials, especially in the Unites States and they spend over USD 750 million provided by the NIH in 2018. Such factors shall boost the augmentation of the market. Competitive Landscape: The key players of the market are Pfizer, QVIA, PAREXEL International Corporation, Pharmaceutical Product Development LLC, Charles River Laboratory, ICON Plc, Wuxi AppTec Inc., PRA Health Sciences, SGS SA, Syneos Health, Chiltern International Ltd., Eli Lilly and Company, Novo Nordisk A/S, Clinipace. FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global clinical trials market by phase, by study design, by indication and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Increased occurrence of appalling diseases, acceptance of novel clinical trial technologies, increased demand for clinical trials from emerging nations are some of the key factors responsible for the proliferation of the market. Furthermore, the soaring insistence for contract research organizations for conducting clinical trials is predicted to boost the clinical trials market growth. CROs are more diversified than pharma companies in performing clinical trials over a wide range of regions and drug development in specific therapeutic areas shall further propel the market growth.
As per the BioOutsource report, 2017, the biosimilar testing is projected to witness a significant growth in the United States and this can be credited to factors like FDA addressing the dearth of clear guidance regarding the usage of biosimilars, particularly the method in which the developers offer drugs similar to the original product. Hospira, in January 2015, developed Epoetin Alfa, a version of Epogen, which received an approval from the FDA within a year. Furthermore, the regional distribution of clinical trials is gradually shifting from developed to developing nations and the increased expenditure of these trials has made the ley players to shift emphasis on regions like Eastern and Central Europe, Latin America and Middle East & Africa for faster recruitment of patients and cost efficiency. Such factors are touted to boost the proliferation of the market. The digitization in researches related to the field of biomedicals has opened lucrative opportunities for the market growth. Acceptance of advanced systems like electronic data capture has helped companies in managing patient data, thereby reducing the cost of monitoring the cost and for improves patient compliance. Furthermore, managing patient data with digitization shall help in reducing the errors related to clinical trials and can satisfy strict regulations. Such factors have contributed to the proliferation of the market.
Market Segmentation:
By Phase
By Study Design
By Indication
By Region
The market is classified into phase, study design, indication and region. The phase segment is categorised into phase I, phase II, phase III and phase IV. The phase III segment held the largest clinical trials market share owing to the huge sample population and the steep cost of these trials. The phase I clinical trials have a sample population of over 100 people, and it helps in evaluating the molecule tolerability which is considered ad the end point of trial approval. Other studies like drug and food interactions are needed to be performed. As per the Food and Drug Association, over 65% of medications move from phase I to phase II. The study design segment is fragmented into observational, interventional and expanded access. The interventional segment is anticipated to lead the market during the forecasted timeframe. The primary motive of interventional trial is to identify about a specific intervention and this method is frequently used for clinical trials. According to the stats provided by the FDA, USA, 2017, over 120,000 trials were performed using this method. Owing to the rising insistence for this study type in clinical trials, this segment is predicted to proliferate at a significant rate during the forecasted time frame. The indication segment is bifurcated into inflammation, pain management, central nervous system conditions, oncology, obesity, cardiovascular, diabetes and others. The oncology segment is anticipated to proliferate at a significant rate during the forecasted timeframe.
Regional Analysis:
The North America region is expected to lead the market owing to rising research and development activities and increased acceptance of these clinical research technologies in the region. North America region has the greatest number of clinical trials, especially in the Unites States and they spend over USD 750 million provided by the NIH in 2018. Such factors shall boost the augmentation of the market.
Competitive Landscape:
The key players of the market are Pfizer, QVIA, PAREXEL International Corporation, Pharmaceutical Product Development LLC, Charles River Laboratory, ICON Plc, Wuxi AppTec Inc., PRA Health Sciences, SGS SA, Syneos Health, Chiltern International Ltd., Eli Lilly and Company, Novo Nordisk A/S, Clinipace.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Clinical Trials Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Clinical Trials Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Clinical Trials Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Clinical Trials Market, By Phase Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Phase I 7.2. Phase II 7.3. Phase III 7.4. Phase IV 8. Clinical Trials Market, By Study Design Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Interventional 8.2. Observational 8.3. Expanded Access 9. Clinical Trials Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Inflammation 9.2. Pain Management 9.3. Central Nervous System Conditions 9.4. Oncology 9.5. Obesity 9.6. Cardiovascular 9.7. Diabetes 9.8. Others 10. North America Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Pfizer 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. QVIA 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. PAREXEL International Corporation 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Pharmaceutical Product Development LLC 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Charles River Laboratory 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. ICON Plc 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Wuxi AppTec Inc. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. PRA Health Sciences 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. SGS SA 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Syneos Health 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Clinical Trials Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Clinical Trials Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Clinical Trials Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Clinical Trials Market, By Phase Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Phase I 7.2. Phase II 7.3. Phase III 7.4. Phase IV
8. Clinical Trials Market, By Study Design Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Interventional 8.2. Observational 8.3. Expanded Access
9. Clinical Trials Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Inflammation 9.2. Pain Management 9.3. Central Nervous System Conditions 9.4. Oncology 9.5. Obesity 9.6. Cardiovascular 9.7. Diabetes 9.8. Others
10. North America Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Clinical Trials Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Pfizer 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. QVIA 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. PAREXEL International Corporation 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Pharmaceutical Product Development LLC 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Charles River Laboratory 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. ICON Plc 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Wuxi AppTec Inc. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. PRA Health Sciences 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. SGS SA 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Syneos Health 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics